BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...M) SARS-CoV-2 envelope protein (SARS-CoV-2 E) Interferon gamma Interleukin-4 (IL-4) (BSF1) Fc gamma receptor...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

...2 PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Hongjiang Li, Staff Writer ACE1702 (ACE-NK-HER2) Acepodia Inc. CD3 CD28 Fc gamma receptor...
BioCentury | Jul 2, 2020
Emerging Company Profile

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

...Patents: One issued covering immunoconjugates of a piperazinyl imidazoquinoline adjuvant bound to any antibody Targets FCGR...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

...receptor may elicit a third layer of anti-tumor immunity. The antibody’s Fc region binds the FCGR...
...TIGIT target at higher densities than other immune cells. Targets: CD155 (PVR) - Poliovirus receptor; FCGR...
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

...Funds raised: $4.3 million Investors: Undisclosed CEO: Guy DiPierro Patents: Undisclosed Targets CD16 (FCGR3) - Fc gamma receptor...
BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing...
BioCentury | Dec 10, 2019
Clinical News

Investors reward Fate for off-the-shelf NK data at ASH

Fate’s 41% gain following presentations at ASH solidifies its iPS cell-derived NK platform’s status as the company’s center of gravity. The company is advancing a series of increasingly complex off-the-shelf NK cell therapies, with a...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Sep 4, 2019
Finance

Nkarta’s $114M series B to fund clinical NK cell programs, manufacturing facility

After stretching its $11.5 million series A round to bring its most advanced preclinical NK cell programs within a year of IND submissions while assembling a management team with expertise ranging from discovery to manufacturing,...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...SIRPA on macrophages. The companies vary in how they deliver tumor-selective “eat me” signals via FCGR...
...against CD47 with an inactive Fc domain (gray ). To deliver “eat me” signals through FCGR...
...from the surfaces of RBCs, reducing anemia induction by the subsequent therapeutic dose. FCGR - Fc gamma receptor (FCGR)...
Items per page:
1 - 10 of 170